ARID1A gene mutation in ovarian and endometrial cancers (Review)

Takashi Takeda, Kouji Banno, Ryuichiro Okawa, Megumi Yanokura, Moito Iijima, Haruko Iriekunitomi, Kanako Nakamura, Miho Iida, Masataka Adachi, Kiyoko Umene, Yuya Nogami, Kenta Masuda, Yusuke Kobayashi, Eiichirou Tominaga, Daisuke Aoki

Research output: Contribution to journalReview articlepeer-review

130 Citations (Scopus)


The ATrich interacting domaincontaining protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome wide analyses with next generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis associated ovarian cancer including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus a small molecule inhibitor of the PI3K/AKT pathway for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular targeted drug can inhibit proliferation of ARID1A mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development survival and progression of cancer cells.

Original languageEnglish
Pages (from-to)607-613
Number of pages7
JournalOncology reports
Issue number2
Publication statusPublished - 2016 Feb


  • ARID1A
  • Chromatin remodeling
  • Ovarian cancer endometrial cancer
  • PI3K/AKT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'ARID1A gene mutation in ovarian and endometrial cancers (Review)'. Together they form a unique fingerprint.

Cite this